A5073798303- Heart Failure Treatment and Management
- Diabetes Treatment and Management
- Cardiovascular Function and Risk Factors
- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Coronary Interventions and Diagnostics
- Metabolism, Diabetes, and Cancer
- Lipoproteins and Cardiovascular Health
- Health Systems, Economic Evaluations, Quality of Life
- Neuroendocrine Tumor Research Advances
- Pancreatic function and diabetes
- GDF15 and Related Biomarkers
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrest and Resuscitation
- Lung Cancer Research Studies
- Genetic Associations and Epidemiology
- Cardiac Imaging and Diagnostics
- Global Public Health Policies and Epidemiology
- Diagnosis and Treatment of Venous Diseases
- Nuclear Receptors and Signaling
- Cardiac Valve Diseases and Treatments
- Macrophage Migration Inhibitory Factor
- Emergency and Acute Care Studies
- Atrial Fibrillation Management and Outcomes
- Neuroblastoma Research and Treatments
Uppsala University
2013-2024
Södertälje Sjukhus
2023-2024
AstraZeneca (Sweden)
2019-2023
Yale University
2020
Karolinska Institutet
2018-2019
Stanford University
2013-2018
Karolinska University Hospital
2018
National University of Science and Technology
2017
Laboratory for Atmospheric and Space Physics
2017
University of Colorado Boulder
2017
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic a left ventricular ejection fraction 40% or less. Whether SGLT2 are effective in higher remains less certain.
Goals of management in patients with heart failure and reduced ejection fraction include reducing death hospitalizations, improving health status (symptoms, physical function, quality life). In the DAPA-HF trial (Dapagliflozin Prevention Adverse-Outcomes Heart Failure), sodium-glucose cotransporter-2 inhibitor, dapagliflozin, improved symptoms fraction. this analysis, we examine effects dapagliflozin on a broad range outcomes, using Kansas City Cardiomyopathy Questionnaire (KCCQ).KCCQ was...
Abstract Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors, originally developed as glucose‐lowering agents, have been shown to reduce heart failure hospitalizations in patients with type diabetes without established failure, and diabetes. Their role preserved mildly reduced ejection fraction remains unknown. Methods Dapagliflozin Evaluation Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (DELIVER) is an international, multicentre, parallel group,...
The optimal platelet inhibition strategy for ACS patients managed without revascularization is unknown. We aimed to evaluate efficacy and safety of ticagrelor vs. clopidogrel in the non-ST-elevation acute coronary syndrome (NSTE-ACS) subgroup PLATO trial, total cohort, subgroups with within 10 days randomization. performed a retrospective analysis primary endpoint cardiovascular death/myocardial infarction/stroke. Among 18 624 patients, 11 080 (59%) were categorized as NSTE-ACS at During...
In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced risk worsening heart failure death patients with ejection fraction. We examined efficacy tolerability relation to background diuretic treatment change therapy after randomization or placebo.
This report describes the baseline clinical profiles and management of DELIVER (Dapagliflozin Evaluation to Improve Lives Patients With Preserved Ejection Fraction Heart Failure) trial participants how these compare with those in other contemporary heart failure preserved ejection fraction trials.The was designed evaluate effects sodium-glucose cotransporter-2 inhibitor dapagliflozin on cardiovascular death, (HF) hospitalization, or urgent HF visits patients mildly reduced left ventricular...
Background: Frailty may modify the risk−benefit profile of certain treatments, and frail patients have reduced tolerance to treatments. Objective: To investigate efficacy dapagliflozin according frailty status, using Rockwood cumulative deficit approach, in DAPA-HF (Dapagliflozin Prevention Adverse Outcomes Heart Failure). Design: Post hoc analysis a phase 3 randomized clinical trial. (ClinicalTrials.gov: NCT03036124) Setting: 410 sites 20 countries. Patients: Patients with symptomatic heart...
Frailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be likely receive new pharmacologic treatments. We investigated the efficacy and tolerability of dapagliflozin according status heart failure mildly reduced or preserved ejection fraction randomized DELIVER (Dapagliflozin Evaluation Improve Lives Patients With Preserved Ejection Fraction Heart Failure).
Background: Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence consequences of iron DAPA-HF trial (Dapagliflozin Prevention Adverse-Outcomes Heart Failure) effect dapagliflozin on markers metabolism. also analyzed outcomes, according to status at baseline. Methods: was defined as a ferritin level <100 ng/mL or transferrin saturation <20% 100 299 ng/mL. Additional biomarkers metabolism, including soluble receptor, erythropoietin,...
Obesity is common and associated with unique phenotypic features in heart failure preserved ejection fraction (HFpEF). Therefore, understanding the efficacy safety of new therapies HFpEF patients obesity important. The effects dapagliflozin were examined according to body mass index (BMI) among Dapagliflozin Evaluation Improve LIVEs Patients With PReserved Ejection Fraction Heart Failure trial.Body was analysed by World Health Organization (WHO) categories as a continuous variable using...
Background: The prevalence of heart failure with mildly reduced or preserved ejection fraction markedly increases age, older individuals disproportionately facing excess risk for mortality and hospitalization. Methods: DELIVER trial (Dapagliflozin Evaluation to Improve the Lives Patients With Preserved Ejection Fraction Heart Failure) randomized patients New York Association functional class II–IV left ventricular >40% either dapagliflozin placebo a median follow-up period 2.3 years. We...
Patients recently hospitalized for heart failure (HF) are at high risk rehospitalization and death.The purpose of this study was to investigate clinical outcomes response dapagliflozin in patients with HF mildly reduced or preserved left ventricular ejection fraction (LVEF) who were enrolled during following hospitalization.The DELIVER (Dapagliflozin Evaluation Improve the LIVES With PReserved Ejection Fraction Heart Failure) trial randomized LVEF >40% placebo. permitted randomization...
Hepatocyte growth factor-scatter factor (HGF-SF) is a pleiotropic cytokine with mito-, morpho-, and motogenic effects on variety of epithelial endothelial cells. HGF-SF activity mediated by the c-met protooncogene, membrane-bound tyrosine kinase. Here, we demonstrate that both genes are expressed in developing adult mammalian brains. mRNA localized neurons, primarily hippocampus, cortex, granule cell layer cerebellum, it also present at high levels ependymal cells, chorioid plexus, pineal...
Cardiac arrest continues to have poor survival in the United States. Recent studies questioned current practice resuscitation. Our emergency medical services system made significant changes adult cardiac resuscitation protocol, including minimizing chest compression interruptions, increasing ratio of compressions ventilation, deemphasizing or delaying intubation, and advocating before initial countershock.This retrospective observational cohort study reviewed all primary ventricular...
Background: Varicose veins are a common problem with no approved medical therapies. Although it is believed that varicose vein pathogenesis multifactorial, there limited understanding of the genetic and environmental factors contribute to their formation. Large-scale studies risk for may highlight important aspects pathophysiology identify groups at increased disease. Methods: We applied machine learning agnostically search in 493 519 individuals UK Biobank. Predictors were further studied...
Risk stratification and the use of specific biomarkers have been proposed for tailoring treatment in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). We investigated prognostic importance high-sensitivity troponin T (hs-TnT), N-terminal pro-brain natriuretic peptide (NT-proBNP), growth differentiation factor-15 (GDF-15) relation to randomized (ticagrelor versus clopidogrel) management strategy (with or without revascularization) NSTE-ACS subgroup Platelet Inhibition Patient...
Patients with heart failure mildly reduced ejection fraction (HFmrEF) and preserved (HFpEF) experience a high burden of symptoms, physical limitations, poor quality life; improving health status is key goal management.In prespecified analysis the DELIVER (Dapagliflozin Evaluation to Improve Lives With Preserved Ejection Fraction Heart Failure) trial, we examine effects dapagliflozin on using Kansas City Cardiomyopathy Questionnaire (KCCQ).The trial randomized patients symptomatic...
Dapagliflozin was recently shown to reduce cardiovascular death or worsening heart failure (HF) events in patients with HF mildly reduced preserved ejection fraction the Evaluation Improve Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial.To evaluate time course benefits dapagliflozin on clinically relevant outcomes this population.The DELIVER trial a global phase 3 clinical that randomized matching placebo. Inclusion criteria included symptomatic HF, left...
Abstract With modern treatments for heart failure with reduced ejection fraction (EF), indicative of impaired cardiac systolic function, patients may exhibit an increase in EF. Limited data are available regarding the clinical management this growing population, categorized as improved EF (HFimpEF), which has a high event rate and been excluded from virtually all prior outcomes trials. In prespecified analysis DELIVER trial ( NCT03619213 ), total 6,263 participants symptomatic left...